Monopar Therapeutics MNPR
$69.00 −$1.29 (-1.84%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $67.35 -2.40%
Open$68.50
Prev close$70.29
Day range$67.36 – $69.86
Volume132.6K
Market cap$467.60M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$7.47M-82.5% YoY
Net profit-$6.20M-80.3% YoY
Diluted EPS-$0.72-50.0% YoY
Free cash flow-$6.17M-156.7% YoY
Operating cash flow-$6.17M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-15.3%
Return on assets-15.0%
Return on invested capital-18.9%
Current ratio43.55
Liabilities / assets2.4%
Cash & investments$129.45M
Total debt$199,806.00
Net cash (debt)$129.25M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $7.47M | $6.64M | $5.23M | $16.70M | $6.16M |
| Selling and Admin Expenses | $3.03M | $1.88M | $1.74M | $6.80M | $2.21M |
| -General & Admin Expense | $3.03M | $1.88M | $1.74M | $6.80M | $2.21M |
| Research & Development | $4.44M | $4.77M | $3.49M | $9.90M | $3.94M |
| Operating Profit | -$7.47M | -$6.64M | -$5.23M | -$16.70M | -$6.16M |
| Net Non-Operating Interest Income (Expense) | $1.27M | $1.30M | $1.33M | $2.99M | $954,434.00 |
| Non-Operating Interest Income | $1.27M | $1.30M | $1.33M | $2.99M | $954,434.00 |
| Pretax Profit | -$6.20M | -$5.31M | -$3.89M | -$13.72M | -$5.20M |
| Net Profit | -$6.20M | -$5.31M | -$3.89M | -$13.72M | -$5.20M |
| Profit from Continuing Operations | -$6.20M | -$5.31M | -$3.89M | -$13.72M | -$5.20M |
| Net Income to Parent Company | -$6.20M | -$5.31M | -$3.89M | -$13.72M | -$5.20M |
| Net Income to Common Stockholders | -$6.20M | -$5.31M | -$3.89M | -$13.72M | -$5.20M |
| Basic EPS | -$0.72 | -$0.62 | -$0.46 | -$1.85 | -$0.64 |
| Diluted EPS | -$0.72 | -$0.62 | -$0.46 | -$1.85 | -$0.64 |
| Other Income (Expense) | – | $32,158.00 | – | – | – |
| Other Non-Operating Income (Expenses) | – | $32,158.00 | – | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $130.25M | $134.98M | $137.98M | $140.72M | $140.72M |
| Total Current Assets | $129.88M | $134.76M | $137.74M | $140.46M | $140.46M |
| Cash and Cash Equivalents & Short-Term Investments | $129.45M | $134.30M | $137.49M | $140.40M | $140.40M |
| -Cash and Cash Equivalents | $52.63M | $52.76M | $52.54M | $61.83M | $61.83M |
| -Short Term Investments | $76.81M | $81.54M | $84.95M | $78.57M | $78.57M |
| Other Current Assets | $434,872.00 | $464,727.00 | $250,903.00 | $63,745.00 | $63,745.00 |
| Total Non-Current Assets | $366,718.00 | $215,120.00 | $239,882.00 | $254,921.00 | $254,921.00 |
| Net PPE | $366,718.00 | $215,120.00 | $239,882.00 | $254,921.00 | $254,921.00 |
| -Gross PPE | $366,718.00 | $215,120.00 | $239,882.00 | $254,921.00 | $254,921.00 |
| Total Liabilities | $3.18M | $4.12M | $2.59M | $2.89M | $2.89M |
| Total Current Liabilities | $2.98M | $4.02M | $2.46M | $2.74M | $2.74M |
| Payables | $2.98M | $4.02M | $2.46M | $2.74M | $2.74M |
| -Accounts Payable | $2.98M | $4.02M | $2.46M | $2.74M | $2.74M |
| Total Non-Current Liabilities | $199,806.00 | $107,828.00 | $131,565.00 | $154,920.00 | $154,920.00 |
| Long Term Debt and Capital Lease Obligation | $199,806.00 | $107,829.00 | $131,565.00 | $154,920.00 | $154,920.00 |
| -Long Term Capital Lease Obligation | $199,806.00 | $107,829.00 | $131,565.00 | $154,920.00 | $154,920.00 |
| Total Equity | $127.07M | $130.85M | $135.39M | $137.83M | $137.83M |
| Stockholders' Equity | $127.07M | $130.85M | $135.39M | $137.83M | $137.83M |
| Capital Stock | $6,762.00 | $6,712.00 | $6,699.00 | $6,692.00 | $6,692.00 |
| -Common Stock | $6,762.00 | $6,712.00 | $6,699.00 | $6,692.00 | $6,692.00 |
| Additional Paid-In Capital | $231.88M | $229.47M | $228.69M | $227.20M | $227.20M |
| Retained Earnings | -$104.91M | -$98.72M | -$93.40M | -$89.51M | -$89.51M |
| Gains/Losses Not Affecting Retained Earnings | $95,233.00 | $91,317.00 | $98,521.00 | $131,389.00 | $131,389.00 |
| Other Non-Current Liabilities | – | -$1.00 | – | – | – |
| Current Accrued Expenses | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$6.17M | -$3.25M | -$3.47M | -$12.20M | -$3.06M |
| Net cash flow from continuing operations | -$6.17M | -$3.25M | -$3.47M | -$12.20M | -$3.06M |
| Net Income from Continuing Operations | -$6.20M | -$5.31M | -$3.89M | -$13.72M | -$5.20M |
| Change in Working Capital | -$1.29M | $1.35M | -$474,202.00 | -$2.61M | $1.42M |
| -Change in Payables and Accrued Expense | -$1.32M | $1.56M | -$287,138.00 | -$2.61M | $1.05M |
| -Change in Other Current Assets | $29,735.00 | -$213,822.00 | -$187,039.00 | $15,404.00 | $371,450.00 |
| -Change In Other Working Capital | $0.00 | $0.00 | -$25.00 | -$9,432.00 | -$5,002.00 |
| Net cash flow from investing | $5.46M | $4.12M | -$5.58M | -$63.45M | -$62.19M |
| Net Cash Flow from Continuing Investing Activities | $5.46M | $4.12M | -$5.58M | -$63.45M | -$62.19M |
| Net Investment Purchase and Sale | $5.46M | $4.12M | -$5.58M | -$63.45M | -$62.19M |
| Financing Cash Flow | $586,232.00 | -$647,389.00 | -$200,203.00 | $91.57M | -$699,296.00 |
| Net Cash Flow from Continuing Financing Activities | $586,232.00 | -$647,389.00 | -$200,203.00 | $91.57M | -$699,296.00 |
| Proceeds from Stock Option Exercised | $884,325.00 | $7,575.00 | $0.00 | $565,171.00 | $544,800.00 |
| Net Other Financing Charges | -$298,093.00 | -$654,964.00 | -$200,203.00 | -$1.13M | -$612,710.00 |
| Ending Cash Balance | $52.63M | $52.76M | $52.54M | $61.83M | $61.83M |
| Net Change in Cash | -$126,015.00 | $220,645.00 | -$9.26M | $15.92M | -$65.94M |
| Beginning Cash Balance | $52.76M | $52.54M | $61.83M | $45.82M | $127.68M |
| Effect of Exchange Rate Changes | $2,611.00 | -$7,142.00 | -$31,628.00 | $97,266.00 | $99,495.00 |
| Free Cash Flow | -$6.17M | -$3.25M | -$3.47M | -$12.20M | -$3.06M |
| Net Common Stock Issuance | – | – | – | $92.14M | -$631,386.00 |
No comments yet — be the first to weigh in on MNPR.
Sign in to join the discussion.